Zdrowie i gospodarka · 21/06/2000

FDA Clears Zantac Efferdose for Sale After Re-evaluation

The US Food and Drug Administration (FDA) has determined that the ranitidine effervescent 75-milligram tablet, marketed as Zantac Efferdose, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for generic versions to be approved.